Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tal Burt

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|February 21, 2017
Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and RecommendationsSavita Nandal, Tal Burt
Pharmacogenomics|July 11, 2013
Pharmacogenomics in early-phase clinical developmentTal Burt, Savita Dhillon
Expert Opinion on Drug Metabolism & Toxicology|April 5, 2013
Microdosing and drug development: past, present and futureGraham Lappin, Robert Noveck, Tal Burt
Journal of Clinical and Preventive Cardiology|February 9, 2016
Research Question, Study Design and Continuous Research Education and Training Exercises (CREATE) ProgramTal Burt, Pooja Sharma, Sanjay Mittal
The International Journal of Neuropsychopharmacology|June 12, 2002
Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysisTal Burt, Sarah H Lisanby, Harold A Sackeim
Journal of Clinical Psychopharmacology|July 20, 2005
Optimal length of antidepressant trials in late-life depressionHarold A Sackeim, Steven P Roose, Tal Burt
The Psychiatric Quarterly|August 26, 2015
Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety DisordersSaurabh Gupta, Kenneth Ronald Gersing, Alaattin Erkanli, et al.
International Clinical Psychopharmacology|December 1, 2005
A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in JapanKunitoshi Kamijima, Tal Burt, Guy Cohen, et al.
BMC Pulmonary Medicine|August 29, 2024
Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a reviewTom M Quinn, Annya M Bruce, Tal Burt, et al.
Clinical and Translational Science|March 12, 2022
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?Tal Burt, Ad F Roffel, Oliver Langer, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|February 21, 2017
Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and RecommendationsSavita Nandal, Tal Burt
Pharmacogenomics|July 11, 2013
Pharmacogenomics in early-phase clinical developmentTal Burt, Savita Dhillon
Expert Opinion on Drug Metabolism & Toxicology|April 5, 2013
Microdosing and drug development: past, present and futureGraham Lappin, Robert Noveck, Tal Burt
Journal of Clinical and Preventive Cardiology|February 9, 2016
Research Question, Study Design and Continuous Research Education and Training Exercises (CREATE) ProgramTal Burt, Pooja Sharma, Sanjay Mittal
The International Journal of Neuropsychopharmacology|June 12, 2002
Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysisTal Burt, Sarah H Lisanby, Harold A Sackeim
Journal of Clinical Psychopharmacology|July 20, 2005
Optimal length of antidepressant trials in late-life depressionHarold A Sackeim, Steven P Roose, Tal Burt
The Psychiatric Quarterly|August 26, 2015
Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety DisordersSaurabh Gupta, Kenneth Ronald Gersing, Alaattin Erkanli, et al.
International Clinical Psychopharmacology|December 1, 2005
A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in JapanKunitoshi Kamijima, Tal Burt, Guy Cohen, et al.
BMC Pulmonary Medicine|August 29, 2024
Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a reviewTom M Quinn, Annya M Bruce, Tal Burt, et al.
Clinical and Translational Science|March 12, 2022
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?Tal Burt, Ad F Roffel, Oliver Langer, et al.
Pageof 3